A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib Plus Best Supportive Care (BSC) Compared to Placebo Plus BSC in Patients With Advanced or Metastatic Gastric Cancer
Phase of Trial: Phase III
Latest Information Update: 11 Aug 2018
At a glance
- Drugs Rivoceranib (Primary)
- Indications Gastric cancer
- Focus Registrational; Therapeutic Use
- Acronyms ANGEL
- Sponsors LSK Biopharma
- 31 Aug 2018 Biomarkers information updated
- 11 Jul 2018 Planned End Date changed from 30 Dec 2018 to 31 Mar 2019.
- 11 Jul 2018 Planned primary completion date changed from 30 Aug 2018 to 28 Feb 2019.